CREKA peptide

Overview

CREKA peptide is a selective non-covalent binding agent targeting fibrin, type IV collagen , and fibronectin, often used as a targeting ligand to modify delivery carriers. CREKA peptide specifically recognizes fibrin, fibronectin, and type IV collagen that are excessively deposited in the tumor microenvironment or fibrotic tissue, mediating the targeted accumulation of the carrier at the lesion site and promoting drug internalization into target cells (such as cancer cells and activated hepatic stellate cells). CREKA peptide can enhance targeted delivery efficiency, increase drug concentration at the lesion site, and reduce systemic side effects.

Application

Products | Products > Peptides | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Signaling Pathways > Cytoskeleton | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Cardiovascular Disease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Signaling Pathways > Collagen

Product Information

• Catalog No.: HY-P10709
• CAS No.: 847058-45-1
• Molecular Formula: C23H43N9O8S
• Molecular Weight: 605.71
• Purity: 99.80%
• Storage: Sealed storage, away from moisture. Powder -80°C, 2 years , -20°C, 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
• Solubility: ≥ 100 mg/mL (165.10 mM); Clear solution
• Availability: In-stock

Source

Original product source